Literature DB >> 26554313

Pharmacokinetics and tissue distribution study of PA-824 in rats by LC-MS/MS.

Libin Wang1, Yetao Ma2, Hongtao Duan3, Jiahui Yao4, Li Liang4, Ruitao Zhang2, Xuejiao Zhou2, Xueying Liu5, Qingwei Wang6, Shengyong Zhang4.   

Abstract

A simple, sensitive and rapid LC-MS/MS method has been developed and validated for determination of PA-824 in rat biological samples using darunavir as internal standard. Chromatographic separation was achieved on an Inertsil(®)ODS3 C18 column (150mm×4.6mm, 5μm) using gradient elution of methanol-0.1% ammonia in water (90:10, v/v) with fast gradient elution at a flow rate of 0.6mL/min and run time of 5min. The mass spectrometer was run in positive electrospray ionization (ESI) mode using multiple reaction monitoring (MRM) to monitor the mass transitions. The optimized ion transition pairs for quantitation were m/z360.1→m/z175.0 for PA-824, m/z548.5→m/z504.2 for IS. The method was validated for accuracy, precision, linearity, range, selectivity, lower limit of quantification (LLOQ), recovery, matrix effect and robustness. All validation parameters met the acceptance criteria according to regulatory guidelines. The LLOQ was 0.05μg/mL. The calibration curves showed a good linearity over the concentration range of 0.05-50μg/mL. The calibration curves for all biological samples showed good linearity (r(2)>0.9978) over the concentration ranges tested. The recoveries obtained for PA-824 were ≥88.8%. The developed method was successfully applied to investigate the pharmacokinetics and tissue distribution of PA-824 in rats following oral administration. It was also the first study to investigate the tissue distribution of PA-824 in rats following oral administration.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  PA-824; Pharmacokinetics; Tissue distribution

Mesh:

Substances:

Year:  2015        PMID: 26554313     DOI: 10.1016/j.jchromb.2015.10.039

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  4 in total

Review 1.  Functionalized Nitroimidazole Scaffold Construction and Their Pharmaceutical Applications: A 1950-2021 Comprehensive Overview.

Authors:  Ria Gupta; Sumit Sharma; Rohit Singh; Ram A Vishwakarma; Serge Mignani; Parvinder Pal Singh
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-30

2.  A validated liquid chromatography tandem mass spectrometry assay for the analysis of pretomanid in plasma samples from pulmonary tuberculosis patients.

Authors:  Andisiwe Malo; Tracy Kellermann; Elisa H Ignatius; Kelly E Dooley; Rodney Dawson; Anton Joubert; Jennifer Norman; Sandra Castel; Lubbe Wiesner
Journal:  J Pharm Biomed Anal       Date:  2020-12-30       Impact factor: 3.935

3.  Delamanid or pretomanid? A Solomonic judgement!

Authors:  Saskia E Mudde; Anna M Upton; Anne Lenaerts; Hannelore I Bax; Jurriaan E M De Steenwinkel
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

Review 4.  Pretomanid for tuberculosis treatment: an update for clinical purposes.

Authors:  Sara Occhineri; Tommaso Matucci; Laura Rindi; Giusy Tiseo; Marco Falcone; Niccolò Riccardi; Giorgio Besozzi
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-09-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.